<DOC>
	<DOCNO>NCT00054535</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . Interleukin-2 may stimulate person 's white blood cell kill melanoma cell . PURPOSE : Phase II trial study effectiveness combine vaccine therapy interleukin-2 treating patient metastatic melanoma .</brief_summary>
	<brief_title>Vaccine Therapy Interleukin-2 Treating Patients With Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate ( partial response complete remission ) patient metastatic melanoma treat vaccinia-tyrosinase vaccine , fowlpox-tyrosinase vaccine , high-dose interleukin-2 . - Determine immunologic response , measure reactivity CD4+ CD8+ T cell serum immunoglobulin tyrosinase melanoma cell , patient treat regimen . OUTLINE : Patients receive vaccinia-tyrosinase vaccine intramuscularly ( IM ) day 1 follow fowlpox-tyrosinase vaccine IM day 15 29 . Patients receive high-dose interleukin-2 ( IL-2 ) IV 15 minute every 8 hour begin day 30 12 dos begin approximately 3 week initial dose . Patients stable disease minor , mixed , partial response may receive additional course fowlpox-tyrosinase vaccine ( 2 dos ) IL-2 absence disease progression unacceptable toxicity . Patients complete response ( CR ) receive 1 additional course beyond achieve CR . Patients follow annually least 5 year . PROJECTED ACCRUAL : A total 19-35 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis metastatic melanoma Measurable disease Disease progression receive prior standard treatment No ocular mucosal primary site No uncontrolled brain metastasis PATIENT CHARACTERISTICS : Age 16 Performance status ECOG 01 Life expectancy More 3 month Hematopoietic WBC least 3,000/mm^3 Platelet count least 90,000/mm^3 No coagulation disorder Hepatic Bilirubin great 1.6 mg/dL ( le 3.0 mg/dL patient Gilbert 's syndrome ) AST/ALT le 3 time normal Hepatitis B surface antigen negative Hepatitis C antibody negative Renal Creatinine great 1.6 mg/dL Cardiovascular No major cardiovascular illness Pulmonary No major respiratory illness Immunologic HIV negative No autoimmune disease No active systemic infection No primary secondary immunodeficiency ( e.g. , hereditary disorder ataxiatelangiectasia WiskottAldrich syndrome acquire immunodeficiency bone marrow transplantation ) No allergy egg No prior allergy untoward reaction smallpox vaccination ( previously vaccinate ) Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No close contact follow individual 2 week vaccinia vaccination : Children 5 year age Pregnant woman Individuals prior active eczema eczematoid skin disorder Individuals acute , chronic , exfoliative skin condition ( e.g. , burn , impetigo , varicella zoster , severe acne , open rash wound ) Immunosuppressed individual No active atopic dermatitis No prior active eczema No active case follow condition : Extensive psoriasis Severe acneiform rash Impetigo Varicella zoster Burns Traumatic pruritic skin condition Open wound No unhealed surgical scar Healed surgical stoma ( e.g. , colostomy ) allow PRIOR CONCURRENT THERAPY : Biologic therapy No prior recombinant vaccinia fowlpox vaccine melanoma No prior vaccination full length tyrosinase protein , vector encode full length protein melanoma Prior individual tyrosinase peptide allow No prior highdose interleukin2 Chemotherapy Not specify Endocrine therapy No concurrent oral , IV , topical , inhaled steroid Radiotherapy Not specify Surgery Recovered prior surgery Other Recovered prior therapy melanoma More 3 week since prior systemic therapy melanoma No concurrent systemic therapy melanoma</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2004</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>